主页 > 医学讨论 >
【drug-news】尼古丁补充疗法有效，但尚存巨大空
Mark Eisenberg (McGill University, Montreal, Quebec, Canada) and colleagues identified 69 randomized, controlled trials involving a total of 32,908 patients that reported biochemically validated measures of smoking abstinence at 6 months and 12 months.
The use of biochemical validation provides additional assurance of self-reported smoking abstinence and enhances the validity of outcomes, the authors explain.
Eisenberg and team found that varenicline, bupropion, and the four nicotine replacement therapies nasal spray, patch, gum, and tablet approximately doubled the odds of smoking abstinence compared with placebo, at odds ratios of 2.41, 2.07, 2.37, 2.07, 2.06, and 1.71, respectively.
Nicotine inhalers also appeared to double the odds, but the results were not statistically significant.
However, most of the randomized, controlled trials in the analysis reported the point prevalence of abstinence at 12 months to be well under 30% among patients in the treatment groups. The rate was even lower with continuous abstinence as the outcome measure.
揇espite the documented efficacy of these [nicotine replacement] agents, the absolute number of patients who were abstinent from smoking at 12 months was low,?the authors caution.
揅onsequently, there remains a need to develop improved smoking cessation agents and to identify optimal cessation strategies, including alternative ways to use existing agents,?the team concludes.
Can Med Assoc J 2008; 179 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 yangfanerxing战友的时间很诡异啊！
Aug 01, 2008 - MedWire News: The current range of pharmacotherapies available to treat tobacco dependence are all more effective than placebo at promoting smoking abstinence at 6 and 12 months, according to the results of a meta-analysis of randomized controlled trials.
2008年8月1日- MedWire新闻：基于对随机对照试验结果的综合分析，目前各种治疗香烟依赖性药物，通过6个月及12个月的试验，均较安慰剂组更有效
Mark Eisenberg (McGill University, Montreal, Quebec, Canada) and colleagues identified 69 randomized, controlled trials involving a total of 32,908 patients that reported biochemically validated measures of smoking abstinence at 6 months and 12 months.
Mark Eisenberg（麦吉尔大学，蒙特利尔，魁北克，加拿大）和同事们进行了69组随机对照试验，涉及32908病例，均采用生化实验方法来评价受试者在6个月和12个月的戒烟效果。
The use of biochemical validation provides additional assurance of self-reported smoking abstinence and enhances the validity of outcomes, the authors explain.
实验者解释：较戒烟效果自我报告，使用生化实验来评价的方法，能提供额外的保证，从而增强实验结果的有效性。
Eisenberg and team found that varenicline, bupropion, and the four nicotine replacement therapies nasal spray, patch, gum, and tablet approximately doubled the odds of smoking abstinence compared with placebo, at odds ratios of 2.41, 2.07, 2.37, 2.07, 2.06, and 1.71, respectively. also appeared to double the odds, but the results were not statistically significant.
Eisenberg和他的研究小组发现varenicline，bupropion（安非他酮）和四种尼古丁替代疗法（鼻腔喷雾剂，贴剂，口香糖，片剂）与使用安慰剂相比，戒烟率提高了近一倍，分别为2.41，2.07，2.37，2.07，2.06 ，1.71。尼古丁吸入剂也能使戒烟几率增加一倍，但结果无统计学意义。
However, most of the randomized, controlled trials in the analysis reported the point prevalence of abstinence at 12 months to be well under 30% among patients in the treatment groups. The rate was even lower with continuous abstinence as the outcome measure.
但是，大多数随机对照试验组数据表明，治疗12月后，戒断者在30%以下，远低于继续吸烟者的数量。
"Despite the documented efficacy of these [nicotine replacement] agents, the absolute number of patients who were abstinent from smoking at 12 months was low," the authors caution.
"Consequently, there remains a need to develop improved smoking cessation agents and to identify optimal cessation strategies, including alternative ways to use existing agents," the team concludes.
作者提醒说“尽管已证明采用尼古丁替代疗法类制剂具有疗效。但12个月后能够戒断的病人数目还是较低 ，因此，该研究小组得出结论：仍然需要开发更好的戒烟药物，并确定最优的治疗方案，包括更有效的使用现有的替代方法制剂”。
http://www.medwire-news.md/48/76711/Respiratory/Nicotine_replacement_therapies_effective,_but_leave_room_for_improvement_.html
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-23 17:11
医学,生命科学网